Long-term patient reported outcomes and hematologic toxicity among patients who received Granulocyte-Colony Stimulating Factors during chemotherapy for early breast cancer

Archive ouverte

Lapidari, Pietro | Gbenou, Arnauld | Havas, Julie | Martin, Elise | Pistilli, Barbara | Martin, Anne-Laure | Everhard, Sibille | Coutant, Charles | Cottu, Paul | Lesur, Anne | Lerebours, Florence | Tredan, Olivier | Vanlemmens, Laurence | Jouannaud, Christelle | Levy, Christelle | Rigal, Olivier | Fournier, Marion | Andre, Fabrice | Vaz-Luis, Ines | Di Meglio, Antonio

Edité par CCSD ; Elsevier -

International audience. We assessed long-term associations of Granulocyte-Colony Stimulating Factors (G-CSF) use with patient-reported outcomes (PROs) and hematologic toxicity among chemotherapy-treated, early-stage breast cancer patients in CANTO (NCT01993498). Among 2920 patients longitudinally followed-up until year-4 after diagnosis, 49% used G-CSF. In multivariable-adjusted mixed-models, EORTC QLQ-C30 pain and summary score were not substantially different between groups (overall adjusted mean difference, use vs no-use [95%CI]: +1.27 [-0.33 to +2.87] and -1.01 [-1.98 to -0.04], respectively). PROs were slightly worse at year-4 among patients receiving G-CSF, although differences were of trivial clinical significance. No major differences were observed in leukocyte or platelet count over time.

• Description
• Sujet/Public
• Outil
• Outil d'anticipation
• Mémoire et thèse
• Gestion